hapabapa
Arbutus Biopharma (NASDAQ:ABUS) quickly soared 19% after a win in a Covid vaccine patent dispute with Moderna (NASDAQ:MRNA), according to a court filing on Wednesday. Moderna fell 0.5%.
The patent decision comes after a Markman hearing in February.
Arbutus (ABUS) and Genevant Sciences, a venture between the company and Roivant Sciences (ROIV) filed against Moderna (MRNA) in 2022 over several patents related to the production and sale of the biotech’s COVID shot. Roivantrose 3%.
Last April, a U.S. appeals court sided with Moderna (MRNA) in a years-long patent dispute between the biotech and Arbutus (ABUS) over messenger-RNA-based COVID vaccine technology.